COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
Antje LindemannAmeeta A PatelNatalie L SilverLin TangZhiyi LiuLi WangNoriaki TanakaXiayu RaoHideaki TakahashiNakachi K MadukaMei ZhaoTseng-Cheng ChenMeng GaoJing WangSteven J FrankWalter N HittelmanGordon B MillsJeffrey N MyersAbdullah A OsmanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
COTI-2 inhibits tumor growth in vitro and in vivo in HNSCC likely through p53-dependent and p53-independent mechanisms. Combination of COTI-2 with cisplatin or radiation may be highly relevant in treating patients with HNSCC harboring TP53 mutations.
Keyphrases